Basilea Pharmaceutica AG
Develops and commercializes anti-infective drugs for severe bacterial and fungal infections.
BSLN | SW
Overview
Corporate Details
- ISIN(s):
- CH0011432447 (+1 more)
- LEI:
- 391200TTZP8EIPSJ5J20
- Country:
- Switzerland
- Address:
- Henric Petri-Strasse 35, 4051 Basel
- Website:
- https://www.basilea.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Basilea Pharmaceutica is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. The company specializes in treatments for severe and life-threatening bacterial and fungal infections. Its key products are the anti-infective brands Cresemba® (isavuconazole) and Zevtera® (ceftobiprole), which it is establishing as global brands. Founded in 2000 as a spin-off from F. Hoffmann-La Roche, Basilea has a proven track record of advancing drugs from research through clinical development to the market, with the goal of becoming a leading company in the hospital anti-infectives sector.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Basilea Pharmaceutica AG and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-16 02:00 |
Regulatory News Service
Basilea receives USD 25 million funding under BARDA agreement to continue to ad…
|
English | 11.0 KB | |
| 2025-09-16 02:00 |
Regulatory News Service
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 25 Mio. für die weitere E…
|
German | 12.7 KB | |
| 2025-08-19 02:00 |
Earnings Release
Basilea on track with strong 2025 half-year results
|
English | 19.5 KB | |
| 2025-08-19 02:00 |
Earnings Release
Basilea mit starkem Halbjahresergebnis 2025 auf Kurs
|
German | 21.4 KB | |
| 2025-08-14 02:00 |
M&A Activity
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
|
English | 11.4 KB | |
| 2025-08-14 02:00 |
M&A Activity
Basilea gibt Einlizenzierung eines neuartigen oralen Antibiotikums bekannt, das…
|
German | 12.9 KB | |
| 2025-07-08 02:00 |
Regulatory News Service
Basilea receives USD 39 million funding under BARDA agreement to continue to ad…
|
English | 11.2 KB | |
| 2025-07-08 02:00 |
Regulatory News Service
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 39 Mio. für die weitere E…
|
German | 13.0 KB | |
| 2025-02-18 01:00 |
Earnings Release
Basilea reports strong 2024 full-year results with significant increase in reve…
|
English | 19.9 KB | |
| 2025-02-18 01:00 |
Earnings Release
Basilea meldet für das Gesamtjahr 2024 ein starkes Ergebnis mit deutlichem Anst…
|
German | 23.1 KB | |
| 2024-12-23 01:00 |
Regulatory News Service
Basilea is awarded additional CARB-X funding to develop new drug candidate from…
|
English | 7.8 KB | |
| 2024-12-23 01:00 |
Regulatory News Service
Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamen…
|
German | 9.2 KB | |
| 2024-12-16 01:00 |
M&A Activity
Basilea announces agreement with Innoviva Specialty Therapeutics for the commer…
|
English | 9.4 KB | |
| 2024-12-16 01:00 |
M&A Activity
Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung v…
|
German | 11.1 KB | |
| 2024-09-19 02:00 |
Earnings Release
Basilea enters into agreement with BARDA to develop novel antifungals and antib…
|
English | 13.7 KB |
Automate Your Workflow. Get a real-time feed of all Basilea Pharmaceutica AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Basilea Pharmaceutica AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-21 | N/A | Executive member | Sell | None | 27,000.00 CHF |
| 2025-04-30 | N/A | Executive member | Sell | None | 17,600.00 CHF |
| 2025-04-23 | N/A | Executive member | Sell | None | 57,396.20 CHF |
| 2025-04-23 | N/A | Non-Executive member | Sell | None | 30,331.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 173,479.91 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 118,568.67 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 41,255.63 CHF |
| 2024-10-28 | N/A | Executive member | Sell | None | 22,500.00 CHF |
| 2024-04-25 | N/A | Executive member | Sell | None | 79,966.26 CHF |
| 2024-04-24 | N/A | Executive member | Sell | None | 23,128.70 CHF |
